Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi

Digital Biomarker company Koneksa announced an extension to its collaboration with Sanofi in central nervous system clinical trials. Sanofi is one of the world’s top biopharmaceutical companies, and Koneksa CEO Chris Benko expressed enthusiasm for the extension: “We’re proud that our long-term partnership has enabled Sanofi’s deployment of digital measures across multiple therapeutic areas and modalities.” He also noted continued collaboration with Sanofi will open an opportunity to study new treatment options for neurological diseases like multiple sclerosis.

Specifically, Koneksa’s work with Safoni will benefit research surrounding tolebrutinib, a BTK inhibitor currently in Phase III trials for all MS subtypes. MS affects nearly three million people worldwide, and progressive MS patients experience a consistent evolution of the disease and currently have no remissions.

Koneksa, a digital biomarker company that centers patients, aims to develop encompassing solutions for remotely collected clinical data. Rob Ellis, PhD, the company’s head of data science, also expressed support for the collaboration, saying, “We’re excited for Sanofi to continue incorporating Koneksa’s digital biomarker platform in their CNS research.” Ellis is hopeful that the collaboration will help researchers gain insights about neurological disease that were once out of reach.

Read the full press release here.